E
China Pharma Holdings, Inc.
CPHI
$0.1412
$0.00473.44%
E
Sell
3/26/2025Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 3/26/2025 due to an increase in the total return index and volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 3/26/2025 due to an increase in the total return index and volatility index.
E
Sell
3/11/2025Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 3/11/2025 due to a decline in the volatility index, solvency index and valuation index. Debt to equity increased from 0.55 to 0.61.
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 3/11/2025 due to a decline in the volatility index, solvency index and valuation index. Debt to equity increased from 0.55 to 0.61.
E
Sell
7/2/2024Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 7/2/2024 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 7/2/2024 due to an increase in the volatility index.
E
Sell
6/14/2024Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 6/14/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 2,524.22% from -$22.3 to -$585.2, and total revenue declined 36.28% from $2.15M to $1.37M.
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 6/14/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 2,524.22% from -$22.3 to -$585.2, and total revenue declined 36.28% from $2.15M to $1.37M.
E
Sell
6/4/2024Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/16/2024Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index and growth index.
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index and growth index.
E
Sell
4/29/2024Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
E
Sell
4/11/2024Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 4/11/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 102.21% from $1.01M to -$22.3, and EBIT declined 66.01% from -$713.5 to -$1.18M.
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 4/11/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 102.21% from $1.01M to -$22.3, and EBIT declined 66.01% from -$713.5 to -$1.18M.
E
Sell
4/1/2024Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 4/1/2024 due to an increase in the volatility index and total return index.
China Pharma Holdings, Inc. (CPHI) was upgraded to E+ from E on 4/1/2024 due to an increase in the volatility index and total return index.
E
Sell
3/13/2024Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 3/13/2024 due to a decline in the volatility index and total return index.
China Pharma Holdings, Inc. (CPHI) was downgraded to E from E+ on 3/13/2024 due to a decline in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
China Pharma Holdings, Inc. (CPHI) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 2.63 to 3.57, and the quick ratio declined from 0.31 to 0.2.
China Pharma Holdings, Inc. (CPHI) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, volatility index and solvency index. Debt to equity increased from 2.63 to 3.57, and the quick ratio declined from 0.31 to 0.2.
D
Sell
8/19/2022Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 8/19/2022 due to a substantial increase in the growth index. Operating cash flow increased 62.04% from -$879.4 to -$333.8, earnings per share increased from -$0.0217 to -$0.0183, and EBIT increased 14.49% from -$911.7 to -$779.6.
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 8/19/2022 due to a substantial increase in the growth index. Operating cash flow increased 62.04% from -$879.4 to -$333.8, earnings per share increased from -$0.0217 to -$0.0183, and EBIT increased 14.49% from -$911.7 to -$779.6.
D
Sell
6/8/2022Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 6/8/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 343.92% from -$198.1 to -$879.4, total revenue declined 44.49% from $2.89M to $1.6M, and EBIT declined 40.54% from -$648.7 to -$911.7.
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 6/8/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 343.92% from -$198.1 to -$879.4, total revenue declined 44.49% from $2.89M to $1.6M, and EBIT declined 40.54% from -$648.7 to -$911.7.
D
Sell
5/5/2022Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 05/05/2022.
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.018 to -$0.0207.
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.018 to -$0.0207.
D
Sell
3/15/2022Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/15/2022 due to a decline in the total return index and volatility index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/15/2022 due to a decline in the total return index and volatility index.
D
Sell
2/3/2022Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 2/3/2022 due to an increase in the volatility index and valuation index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 2/3/2022 due to an increase in the volatility index and valuation index.
D
Sell
11/22/2021Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 11/22/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0181 to -$0.018.
China Pharma Holdings, Inc. (CPHI) was upgraded to D from D- on 11/22/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0181 to -$0.018.
D
Sell
11/8/2021Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and volatility index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and volatility index.
D
Sell
10/20/2021Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 10/20/2021 due to a decline in the volatility index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 10/20/2021 due to a decline in the volatility index.
D
Sell
10/5/2021Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 10/5/2021 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 10/5/2021 due to an increase in the volatility index.
D
Sell
5/18/2021Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 5/18/2021 due to a decline in the valuation index, solvency index and total return index. The quick ratio declined from 0.13 to 0.1, and debt to equity increased from 0.93 to 1.01.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 5/18/2021 due to a decline in the valuation index, solvency index and total return index. The quick ratio declined from 0.13 to 0.1, and debt to equity increased from 0.93 to 1.01.
D
Sell
5/13/2021Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 5/13/2021 due to a substantial increase in the growth index, solvency index and valuation index. Operating cash flow increased 249.24% from -$224.4 to $334.9, the quick ratio increased from 0.08 to 0.13, and total revenue increased 22.09% from $2.4M to $2.93M.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 5/13/2021 due to a substantial increase in the growth index, solvency index and valuation index. Operating cash flow increased 249.24% from -$224.4 to $334.9, the quick ratio increased from 0.08 to 0.13, and total revenue increased 22.09% from $2.4M to $2.93M.
D
Sell
2/4/2021Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 2/4/2021 due to a decline in the valuation index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 2/4/2021 due to a decline in the valuation index.
D
Sell
1/20/2021Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 1/20/2021 due to a major increase in the total return index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 1/20/2021 due to a major increase in the total return index.
D
Sell
11/16/2020Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 11/16/2020 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0003 to -$0.0232, EBIT declined 1,370% from $75 to -$952.5, and operating cash flow declined 345.51% from $91.4 to -$224.4.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 11/16/2020 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.0003 to -$0.0232, EBIT declined 1,370% from $75 to -$952.5, and operating cash flow declined 345.51% from $91.4 to -$224.4.
D
Sell
7/22/2020Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 7/22/2020 due to an increase in the total return index, valuation index and volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 7/22/2020 due to an increase in the total return index, valuation index and volatility index.
D
Sell
7/7/2020Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/7/2020 due to a large decline in the total return index, solvency index and valuation index. The quick ratio declined from 0.17 to 0.09, and debt to equity increased from 0.71 to 0.78.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/7/2020 due to a large decline in the total return index, solvency index and valuation index. The quick ratio declined from 0.17 to 0.09, and debt to equity increased from 0.71 to 0.78.
D
Sell
5/1/2020Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D- on 5/1/2020 due to an increase in the growth index and volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D- on 5/1/2020 due to an increase in the growth index and volatility index.
D
Sell
4/1/2020Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D+ on 4/1/2020 due to a noticeable decline in the growth index, efficiency index and solvency index. Net income declined 2,574.08% from -$701 to -$18.75M, earnings per share declined from -$0.0161 to -$0.4301, and operating cash flow declined 268.55% from $471.9 to -$795.4.
China Pharma Holdings, Inc. (CPHI) was downgraded to D- from D+ on 4/1/2020 due to a noticeable decline in the growth index, efficiency index and solvency index. Net income declined 2,574.08% from -$701 to -$18.75M, earnings per share declined from -$0.0161 to -$0.4301, and operating cash flow declined 268.55% from $471.9 to -$795.4.
D
Sell
2/4/2020Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 2/4/2020 due to an increase in the growth index, total return index and solvency index. Debt to equity declined from 0.29 to 0.23, earnings per share increased from -$0.0192 to -$0.0161, and EBIT increased 14.32% from -$753 to -$645.2.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 2/4/2020 due to an increase in the growth index, total return index and solvency index. Debt to equity declined from 0.29 to 0.23, earnings per share increased from -$0.0192 to -$0.0161, and EBIT increased 14.32% from -$753 to -$645.2.
D
Sell
7/5/2019Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/5/2019 due to a noticeable decline in the total return index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/5/2019 due to a noticeable decline in the total return index.
D
Sell
6/6/2019Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 6/6/2019 due to a noticeable increase in the total return index, efficiency index and volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 6/6/2019 due to a noticeable increase in the total return index, efficiency index and volatility index.
D
Sell
5/22/2019Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 5/22/2019 due to a decline in the total return index and solvency index. The quick ratio declined from 0.23 to 0.22.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 5/22/2019 due to a decline in the total return index and solvency index. The quick ratio declined from 0.23 to 0.22.
D
Sell
5/7/2019Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 5/7/2019 due to an increase in the growth index, efficiency index and volatility index. EBIT increased 46.58% from -$1.93M to -$1.03M, and total revenue increased 41.08% from $2.3M to $3.24M.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 5/7/2019 due to an increase in the growth index, efficiency index and volatility index. EBIT increased 46.58% from -$1.93M to -$1.03M, and total revenue increased 41.08% from $2.3M to $3.24M.
D
Sell
2/20/2019Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 2/20/2019 due to a decline in the total return index and valuation index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 2/20/2019 due to a decline in the total return index and valuation index.
D
Sell
12/31/2018Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 12/31/2018 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 321.21% from -$399.3 to $883.3.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 12/31/2018 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 321.21% from -$399.3 to $883.3.
D
Sell
4/4/2018Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from C- on 4/4/2018 due to a substantial decline in the growth index, efficiency index and solvency index. Net income declined 529.83% from -$2.2M to -$13.83M, earnings per share declined from -$0.0504 to -$0.3173, and EBIT declined 91.52% from -$871.3 to -$1.67M.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from C- on 4/4/2018 due to a substantial decline in the growth index, efficiency index and solvency index. Net income declined 529.83% from -$2.2M to -$13.83M, earnings per share declined from -$0.0504 to -$0.3173, and EBIT declined 91.52% from -$871.3 to -$1.67M.
C
Hold
3/1/2018Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to C- from D+ on 3/1/2018 due to a substantial increase in the total return index.
China Pharma Holdings, Inc. (CPHI) was upgraded to C- from D+ on 3/1/2018 due to a substantial increase in the total return index.
D
Sell
1/11/2018Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 1/11/2018 due to a large increase in the growth index, volatility index and efficiency index. Operating cash flow increased 186.56% from -$783.3 to $678, EBIT increased 24.46% from -$1.15M to -$871.3, and total revenue increased 8.4% from $2.92M to $3.16M.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 1/11/2018 due to a large increase in the growth index, volatility index and efficiency index. Operating cash flow increased 186.56% from -$783.3 to $678, EBIT increased 24.46% from -$1.15M to -$871.3, and total revenue increased 8.4% from $2.92M to $3.16M.
D
Sell
3/31/2017Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/31/2017 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0402 to -$0.0796.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/31/2017 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0402 to -$0.0796.
D
Sell
3/24/2017Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 3/24/2017 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 215.84% from -$748.3 to $866.8, EBIT increased 35.45% from -$1.4M to -$903.1, and earnings per share increased from -$0.06 to -$0.0402.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 3/24/2017 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 215.84% from -$748.3 to $866.8, EBIT increased 35.45% from -$1.4M to -$903.1, and earnings per share increased from -$0.06 to -$0.0402.
D
Sell
3/24/2016Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/24/2016 due to a major decline in the volatility index and total return index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 3/24/2016 due to a major decline in the volatility index and total return index.
D
Sell
3/9/2016Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 3/9/2016 due to an increase in the volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 3/9/2016 due to an increase in the volatility index.
D
Sell
1/12/2016Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index, efficiency index and solvency index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index, efficiency index and solvency index.
D
Sell
12/28/2015Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 12/28/2015 due to an increase in the growth index. Earnings per share increased from -$0.0944 to -$0.1, and EBIT increased 4.82% from -$3.8M to -$3.99M.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 12/28/2015 due to an increase in the growth index. Earnings per share increased from -$0.0944 to -$0.1, and EBIT increased 4.82% from -$3.8M to -$3.99M.
D
Sell
9/21/2015Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 9/21/2015 due to a decline in the total return index.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 9/21/2015 due to a decline in the total return index.
D
Sell
8/17/2015Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 8/17/2015 due to an increase in the growth index. Operating cash flow increased 23,240.91% from -$2.2 to -$513.5.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 8/17/2015 due to an increase in the growth index. Operating cash flow increased 23,240.91% from -$2.2 to -$513.5.
D
Sell
7/8/2015Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/8/2015 due to a significant decline in the volatility index, growth index and efficiency index. Operating cash flow declined 100.11% from $1.98M to -$2.2, EBIT declined 8.69% from -$8.4M to -$7.67M, and earnings per share declined from -$0.2 to -$0.183.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 7/8/2015 due to a significant decline in the volatility index, growth index and efficiency index. Operating cash flow declined 100.11% from $1.98M to -$2.2, EBIT declined 8.69% from -$8.4M to -$7.67M, and earnings per share declined from -$0.2 to -$0.183.
D
Sell
4/2/2015Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D+ from C- on 4/2/2015 due to a noticeable decline in the growth index and efficiency index. Total capital declined 7.25% from $133.89M to $124.17M.
China Pharma Holdings, Inc. (CPHI) was downgraded to D+ from C- on 4/2/2015 due to a noticeable decline in the growth index and efficiency index. Total capital declined 7.25% from $133.89M to $124.17M.
C
Hold
2/12/2015Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to C- from D+ on 2/12/2015 due to a noticeable increase in the volatility index and total return index.
China Pharma Holdings, Inc. (CPHI) was upgraded to C- from D+ on 2/12/2015 due to a noticeable increase in the volatility index and total return index.
D
Sell
11/26/2014Upgraded
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 11/26/2014 due to a noticeable increase in the growth index and volatility index.
China Pharma Holdings, Inc. (CPHI) was upgraded to D+ from D on 11/26/2014 due to a noticeable increase in the growth index and volatility index.
D
Sell
10/29/2014Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 10/29/2014 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 103.1% from $2.49M to -$77.1, total revenue declined 13.72% from $7.11M to $6.13M, and total capital declined 5.7% from $148.65M to $140.18M.
China Pharma Holdings, Inc. (CPHI) was downgraded to D from D+ on 10/29/2014 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 103.1% from $2.49M to -$77.1, total revenue declined 13.72% from $7.11M to $6.13M, and total capital declined 5.7% from $148.65M to $140.18M.
D
Sell
6/12/2014Downgrade
China Pharma Holdings, Inc. (CPHI) was downgraded to D+ from C- on 6/12/2014 due to a noticeable decline in the efficiency index, total return index and solvency index. Net income declined 77.08% from -$10.43M to -$2.39M, debt to equity increased from 0.14 to 0.15, and the quick ratio declined from 4.27 to 4.08.
China Pharma Holdings, Inc. (CPHI) was downgraded to D+ from C- on 6/12/2014 due to a noticeable decline in the efficiency index, total return index and solvency index. Net income declined 77.08% from -$10.43M to -$2.39M, debt to equity increased from 0.14 to 0.15, and the quick ratio declined from 4.27 to 4.08.
AMEX
04/11/2025 3:59PM Eastern
Quotes delayed
